Open Orphan: Scaling Up, Leveraging Valuable Assets
Open Orphan PLC (LON:ORPH) is a specialist contract research organisation (CRO) offering pharmaceutical services focused on orphan drugs. It is a world leader in the testing of vaccines and anti-viral treatments through the use of human challenge study services. With its hVIVO subsidiary now integrated, Open Orphan (ORPH) is leveraging its capabilities to the full, growing the top line and targeting near term profitability by delivering specialist pharma services across its hVIVO and Venn subsidiaries. The game-changing target to develop a coronavirus human viral challenge model would provide a unique service, potentially accelerating the development of vaccines and anti-viral treatments for COVID-19. ORPH looks to license FLU-v, a differentiated universal flu vaccine, developed by its 49% owned joint venture Imutex acquired through the hVIVO merger, offering risk-free upside prospects.
Quick facts: Open Orphan PLC
Price: 20.75 GBX
Market Cap: £139.2 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...FOR OUR FULL DISCLAIMER CLICK HERE
LEGAL NOTICE – IMPORTANT – PLEASE READ:
Proactive Research is a trading name of Proactive Investors Limited which is regulated and authorised by the Financial Conduct Authority (FCA) under firm registration...FOR OUR FULL DISCLAIMER CLICK HERE